Zydus Lifesciences Limited Regulatory Clarification
Date of Communication: July 14, 2026
Nature of Query: The National Stock Exchange of India Limited (NSE) requested clarification on a news item appearing in media/publication regarding the company.
Company's Clarification:
Zydus Lifesciences Limited provided a three-point response to the exchange's query:
- Regulatory Disclosure Status: Confirmed there are no negotiations or events requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Materiality Assessment: Stated that the event referenced in the news (passing of order by Hon'ble Delhi High Court to temporarily restrict the Company's supply of the cancer drug IkraTM) is not material according to both the company's materiality policy and the provisions of the Listing Regulations.
- Trading Impact: Reported that due to the news, there was no material movement in the trading of the company's equity shares on July 14, 2026. The company further stated it believes there is no material impact of this event on the company.
Regulatory Compliance: The company explicitly referenced compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 (Listing Regulations), particularly Regulation 30 regarding disclosure requirements. The response emphasizes the company's commitment to complying with all applicable disclosure requirements and keeping stock exchanges informed of any material developments when required.
Topic Tags: Regulatory Response, Court Order, Drug Supply Restriction, Compliance Disclosure, Materiality Assessment